AA
EGRX

ALPS Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

ALPS Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,535
Closed -$335K – 1204
2022
Q2 		$335K Buy
+7,535
New +$346K ﹤0.01% 717
2021
Q2 		– Sell
-23,570
Closed -$984K – 923
2021
Q1 		$984K Sell
23,570
-1,025
-4% -$47.6K 0.01% 400
2020
Q4 		$1.15M Buy
+24,595
New +$1.15M 0.01% 373
2020
Q1 		– Sell
-5,913
Closed -$355K – 952
2019
Q4 		$355K Sell
5,913
-258
-4% -$15.4K ﹤0.01% 711
2019
Q3 		$349K Sell
6,171
-1,779
-22% -$100K ﹤0.01% 758
2019
Q2 		$443K Sell
7,950
-420
-5% -$21.9K ﹤0.01% 574
2019
Q1 		$423K Buy
8,370
+1,612
+24% +$71.7K ﹤0.01% 592
2018
Q4 		$272K Sell
6,758
-336
-5% -$17.3K ﹤0.01% 822
2018
Q3 		$492K Sell
7,094
-1,104
-13% -$83.7K ﹤0.01% 644
2018
Q2 		$620K Sell
8,198
-384
-4% -$24.2K ﹤0.01% 475
2018
Q1 		$452K Buy
8,582
+1,288
+18% +$74.9K ﹤0.01% 708
2017
Q4 		$390K Sell
7,294
-500
-6% -$27.8K ﹤0.01% 685
2017
Q3 		$465K Buy
7,794
+1,809
+30% +$109K ﹤0.01% 642
2017
Q2 		$472K Buy
5,985
+16
+0.3% +$1.31K ﹤0.01% 564
2017
Q1 		$495K Buy
+5,969
New +$444K ﹤0.01% 436
2016
Q4 		– Sell
-19,933
Closed -$1.4M – 736
2016
Q3 		$1.4M Sell
19,933
-2,032
-9% -$113K 0.01% 206
2016
Q2 		$852K Buy
+21,965
New +$915K 0.01% 211

Other funds holding EGRX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ALPS Advisors's EGRX Position: Q3 2022 in Review

ALPS Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 7,535 shares — an estimated $335K sold.

ALPS Advisors first reported a position in EGRX in Q2 2016 and held it in 17 quarters. The position peaked at $1.4M in Q3 2016. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

  • ALPS Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • ALPS Advisors sold 7,535 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $335K.
  • ALPS Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 17 quarters.
  • ALPS Advisors's Eagle Pharmaceuticals, Inc. position peaked at $1.4M in Q3 2016.
  • 153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on ALPS Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.